<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03187002</url>
  </required_header>
  <id_info>
    <org_study_id>IRB-41589</org_study_id>
    <nct_id>NCT03187002</nct_id>
  </id_info>
  <brief_title>Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Control During First Trimester Abortion</brief_title>
  <official_title>Transcutaneous Electrical Nerve Stimulation (TENS) for Pain Control During First Trimester Abortion: A Blinded Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_unapproved_device>No</is_unapproved_device>
    <is_ppsd>No</is_ppsd>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      High-frequency, high-intensity transcutaneous electrical nerve-stimulation (TENS) is an
      inexpensive and non-invasive pain control approach. TENS, pulsating electrical currents that
      activate underlying nerves, does not have drug interactions or risk of overdose. Cochrane
      review of TENS for acute pain found inconclusive evidence. One previous abortion trial
      comparing TENS to IV sedation only looked at pain control in the recovery room. The
      investigators propose a randomized controlled trial comparing TENS to IV sedation (in
      conjunction with local anesthesia) among women presenting for first-trimester surgical
      abortion. Primary outcome will be perceived pain by Visual Analogue Scale (VAS) during
      cervical dilation.
    </textblock>
  </brief_summary>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">October 16, 2017</start_date>
  <completion_date type="Anticipated">July 2018</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cervical Dilation Pain</measure>
    <time_frame>immediately following cervical dilation</time_frame>
    <description>Pain with cervical dilation, assessed by visual analogue scale (VAS, 0-100mm)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">142</enrollment>
  <condition>Abortion in First Trimester</condition>
  <arm_group>
    <arm_group_label>Transcutaneous electrical nerve stimulation (TENS)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transcutaneous electrical nerve stimulation (TENS)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Moderate IV Sedation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fentanyl, versed</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcutaneous electrical nerve stimulation (TENS)</intervention_name>
    <description>Transcutaneous electrical nerve-stimulation (TENS) is a nonpharmacologic means of pain control that delivers electrical currents through the skin. These pulses of electrical current reduce pain by peripheral and central mechanisms, TENS actives descending inhibitory systems in the central nervous system to reduce sensitivity to pain (hypoalgesia). Assessment of previous TENS research identifies intensity as a critical factor in efficacyâ€”documenting high intensity as the best means of pain control, as the higher pulse allows for deeper tissue afferents to be activated. TENS has been researched in a number of settings as pain control, including cancer pain, lower back pain, labor, and a range of gynecologic procedures and disorders.</description>
    <arm_group_label>Transcutaneous electrical nerve stimulation (TENS)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Moderate IV Sedation</intervention_name>
    <description>IV sedation with fentanyl and versed</description>
    <arm_group_label>Moderate IV Sedation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SHAM: Transcutaneous electrical nerve stimulation (TENS)</intervention_name>
    <description>Sham Transcutaneous electrical nerve stimulation (TENS) to ensure blinding</description>
    <arm_group_label>Moderate IV Sedation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>SHAM: Moderate IV Sedation</intervention_name>
    <description>Sham IV to ensure blinding</description>
    <arm_group_label>Transcutaneous electrical nerve stimulation (TENS)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:

          -  Presenting for surgical abortion

          -  Gestational age &lt;12 weeks

          -  &lt; 18 years of age

          -  Agrees to be randomized

        Exclusion criteria:

          -  Allergy to study medications (lidocaine, fentanyl, midazolam)

          -  &gt; 18 years of age

          -  Fetal demise

          -  Pre-procedure use of misoprostol

          -  No means of transportation following procedure
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Principal Investigator, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Planned Parenthood Mar Monte</name>
      <address>
        <city>San Jose</city>
        <state>California</state>
        <zip>95126</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 13, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

